A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS [obatoclax] Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)

Trial Profile

A Multi-Center, Open-Label, Phase I/II Study of Single-Agent GX15-070MS [obatoclax] Administered Every 2 to 3 Weeks to Patients With Previously-Treated Chronic Lymphocytic Leukemia (CLL)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2010

At a glance

  • Drugs Obatoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gemin X Biotechnologies
  • Most Recent Events

    • 29 Oct 2008 Results published in the online version of Blood.
    • 20 Jan 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top